ADA: Unlike currently available blood glucose monitors, which require finger prick or other invasive testing for calibration one or more times daily, a new blood glucose monitor presented at the American Diabetes Association 62nd Scientific Sessions in San Francisco, California, is completely noninvasive.
Read More »Cholesterol Drugs Increase Risk of Nerve Damage
Statins may increase the risk of nerve damage. But benefits still far outweigh the risk of neuropathy, which remains very low.
Read More »For Men Only: Diabetes May Boost Risk of Alzheimer’s
Diabetes mellitus appears to be associated with a markedly increased risk of Alzheimer’s disease, but only in men. Said, Steven D. Edland, Ph.D., at the annual meeting of the American Academy of Neurology.
Read More »Issue 110 Item 15 ADA: Nuts May Lower Risk of Diabetes
Nut consumption was inversely associated with risk of diabetes
Read More »Issue 111 Item 19 INGAP Peptide – An Initiator of Beta Cell Growth
You will be hearing more about INGAP in upcoming newsletters Recent studies have shown that induction of islet neogenesis from adult pancreatic stem cells has the potential for restoring beta cell mass in diabetes.
Read More »Issue 111 Item 2 ADA: Good Glycemic Control Is Not Enough in Managing Diabetes
Priorities are misplaced because coronary artery disease is the major cause of death in patients with type 2 diabetes mellitus
Read More »Issue 107 Item 1 New Impotence Drug Makes Sex More Spontaneous
Men with erectile dysfunction can have sexual intercourse for up to 36 hours after taking a single dose of Cialis
Read More »Issue 109 Item 15 Cost-effectiveness of Intensive Glycemic Control
Controlling blood pressure, blood glucose and cholesterol reduces costs and improves the quality of life.
Read More »ADA: A ‘Breakthrough’ for Diabetic Peripheral Neuropathy
LY333531, is the first drug to attack the cause of nerve-damaging diabetic peripheral neuropathy.
Read More »Issue 111 Item 18 Cozaar (Losartan) Lowered Risk Of Total Mortality In Patients
Treatment with losartan resulted in a 24 per cent reduction in the primary composite endpoint of cardiovascular death, stroke and heart attack.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.